Jeena Sikho Lifecare (JSLL) Q3 25/26 earnings summary

Executive summary

• Standalone Q3 FY26 revenue from operations was Rs 22,166.47 lakh and net profit was Rs 6,672.67 lakh, both sharply higher YoY; the Board approved unaudited standalone and consolidated results.

• Q3 EBITDA was ₹10,080 lakh, up 240% YoY, with a 45% margin; growth reflected rising volumes across services and products.

• Consolidated figures were presented for the first time; comparative consolidated-period figures represent standalone results, limiting like-for-like comparison.

Financial highlights

• Standalone Q3 revenue from operations was Rs 22,166.47 lakh vs Rs 11,569.20 lakh YoY; 9M revenue was Rs 58,579.57 lakh vs Rs 32,982.13 lakh.

• Standalone Q3 net profit was Rs 6,672.67 lakh vs Rs 1,321.08 lakh YoY; 9M net profit was Rs 17,682.39 lakh vs Rs 5,460.36 lakh.

• Consolidated Q3 revenue from operations was Rs 22,167.97 lakh and net profit attributable to owners was Rs 6,666.09 lakh; 9M figures were Rs 58,581.07 lakh and Rs 17,671.95 lakh.

• Q3 EBITDA was ₹10,080 lakh, up 240% YoY and 9% QoQ; EBIT was ₹8,959 lakh, up 324% YoY and 10% QoQ.

• Finance costs fell 18% YoY and 29% QoQ to ₹310 lakh; other income rose 558% YoY and 78% QoQ to ₹257 lakh.

Outlook and guidance

• 475+ beds are under development; planned additions at existing and new facilities are intended to support services growth.

• Priorities include higher utilization, new centres, OTC medicine sales, product launches, cashless insurance, government and AYUSH coverage, and UAE-led overseas expansion.

• The Jeena Sikho Health Card is planned to offer customer value and convenience; further details are expected in upcoming quarters.